ストックスクリーナーアプリを入手
1.75
12.90%
0.20
アフターアワーズ：
1.75
前日終値:
$1.55
開ける：
$1.5407
24時間の取引高:
41,105
Relative Volume:
1.17
時価総額：
$20.22M
収益：
-
当期純損益:
$-13.59M
株価収益率:
-1.6204
EPS:
-1.08
ネットキャッシュフロー:
$-19.79M
1週間 パフォーマンス:
+16.67%
1か月 パフォーマンス:
-5.41%
6か月 パフォーマンス:
-50.14%
1年 パフォーマンス:
-70.83%
1日の値動き範囲:
$1.524
$1.80
1週間の範囲:
$1.48
$1.80
52週間の値動き範囲:
$1.43
$6.0199
Calcimedica Inc Stock (CALC) Company Profile
CALC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
1.75 | 20.22M | 0 | -13.59M | -19.79M | -1.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Calcimedica Inc (CALC) 最新ニュース
Bristol-Myers Squibb (NYSE:BMY) vs. CalciMedica (NASDAQ:CALC) Critical Review - Defense World
CalciMedica (NASDAQ:CALC) Shares Up 0.7% – Here’s Why - Defense World
CalciMedica's Breakthrough Research Takes Center Stage at Two Elite Medical Conferences - Stock Titan
Analysts Offer Predictions for CalciMedica Q4 Earnings - Defense World
CalciMedica Inc. (CALC) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Corient Private Wealth LLC Buys New Shares in CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica (NASDAQ:CALC) Receives “Buy” Rating from HC Wainwright - Defense World
Graybug Vision stock hits 52-week low at $1.81 - Investing.com India
Graybug Vision stock hits 52-week low at $1.81 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $16 target on CalciMedica stock - Investing.com Australia
CalciMedica’s Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating - TipRanks
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference - PR Newswire
CalciMedica says cash sufficient to fund operating plan into mid-2026 - TipRanks
CALCIMEDICA Earnings Results: $CALC Reports Quarterly Earnings - Nasdaq
CalciMedica Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates - Citizen Tribune
Calcimedica Reports 2024 Financial Results And Provides Clinical & Corporate Updates - MarketScreener
CalciMedica (CALC) to Release Earnings on Thursday - The AM Reporter
CalciMedica Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Atria Investments Inc Buys 7,509 Shares of CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica (CALC) Expected to Announce Quarterly Earnings on Thursday - Defense World
Graybug Vision stock hits 52-week low at $1.83 amid challenges - Investing.com
Head to Head Survey: Rani Therapeutics (NASDAQ:RANI) vs. CalciMedica (NASDAQ:CALC) - The AM Reporter
Rani Therapeutics (NASDAQ:RANI) versus CalciMedica (NASDAQ:CALC) Financial Contrast - Defense World
Promising Phase 2 Results and Market Potential Drive Buy Rating for CalciMedica’s Auxora - TipRanks
Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Increases By 35.0% - Defense World
Latham & Watkins Advises CalciMedica in Secured Growth Financing - Latham & Watkins LLP
CalciMedica secures $32.5 million credit facility By Investing.com - Investing.com Canada
CalciMedica secures credit facility for up to $32.5M - MSN
CalciMedica Secures Credit Facility For Up To $32.5 Million -March 05, 2025 at 07:44 am EST - Marketscreener.com
CalciMedica secures $32.5 million credit facility - Investing.com India
CalciMedica Secures Credit Facility for Up to $32.5 Million - Finansavisen
CalciMedica (NASDAQ:CALC) Given “Buy” Rating at HC Wainwright - Defense World
Graybug Vision stock hits 52-week low at $1.95 amid challenges - Investing.com
CalciMedica reports reduced mortality in AKI trial with Auxora - Investing.com
CalciMedica Highlights Auxora’s Potential in COVID-19 Treatment - TipRanks
CalciMedica reports reduced mortality in AKI trial with Auxora By Investing.com - Investing.com South Africa
CalciMedica’s Auxora shows mortality reduction in COVID-19 pneumonia trial - TipRanks
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica, Inc. (CALC): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
12 Penny Stocks with Insider Buying in 2025 - Insider Monkey
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Longview News-Journal
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors - Victoria Advocate
CalciMedica announces board changes By Investing.com - Investing.com Australia
CalciMedica appoints new director amid clinical trials By Investing.com - Investing.com Nigeria
CalciMedica announces board changes - Investing.com
CalciMedica appoints new director amid clinical trials - Investing.com
CalciMedica Announces Board Changes and New Appointment - TipRanks
CalciMedica, Inc. (NASDAQ:CALC) Shares Acquired by Geode Capital Management LLC - Defense World
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) - The Eastern Progress Online
Calcimedica Inc (CALC) 財務データ
収益
当期純利益
現金流量
EPS
0.47%
2.63%
大文字化:
|
ボリューム (24 時間):